A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection

Akrouf, Kafya A; Gad, Amal A; Ibrahim, Eman A; Kassem, Mohamed F; Abdelmonem, Fatehia M; Kholy, Naglaa E

doi:10.21608/scumj.2016.116298

A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection

Document Type : Original Article

Authors

¹ Amiri Hospital, Kuwait, Thanian al Ghanem Gastrointestinal Centre, Kuwait.

² Amiri Hospital, Kuwait, Thanian al Ghanem Gastrointestinal Centre, Kuwait. Department of Internal Medicine, School of Medicine, Suez Canal University, Egypt.

³ Department of Tropical Medicine, Al Azhar University, Egypt

10.21608/scumj.2016.116298

Abstract

Aim: To assess the long-term efficacy and safety of Entecavir in the treatment of CHB. Patients and Methods: This study included 70 CHB consecutive patients on Entecavir for at least 36 months retrospectively, followed prospectively for 18 months. Results: twenty-three (32.8) were HBeAg +ve, 47.1% naive, 22 (31.4%) females, with a mean age of 42.9±13, 14 (20%) cirrhotic and 1 (1.4%) decompensated. There were no significant differences in the pre-treatment HBV-DNA level among HBeAg (+ve) and HBeAg-ve group, with a mean± SD log 10 of 7.9±5.4 and 7.4±5.0 respectively. (P= 0.237). There was a significant viral load reduction after 6 months Entecavir therapy that was more in the HBeAg –ve compared to HBeAg +ve group. In HBeAg +ve, 19 (82.61%) had HBV-DNA suppression after a median of 7 months, compared to 100% in HBeAg –ve with a median of 5 months (P <0.05). In the HBeAg-ve group; one (2.13%) had HBsAg loss at 45 months compared to none in HBeAg (+ve) group (P <0.001), while in the HBeAg (+ve) group; 5 (21.74%) showed HBeAg clearance after a median of 16 months. Multivariate analysis identified HBeAg negative status, as the only independent factor affecting viral suppression. The drug showed 100% safety. None showed hepatic decompensation, HCC or reported death. Conclusions: In real-life data; long term Entecavir treatment effectively sup-pressed HBV. Entecavir is considered an effective and safe treatment for CHB patients compared to 82% in HBeAg (+ve) group. Entecavir is considered an effective and safe choice on long term use for treatment CHB patients.

Keywords